Characteristics | Antiviral therapy | ||
---|---|---|---|
Baseline | 6 months | 12 months | |
ALT normal/total [n (%)] | 3/32 (9.4%) | 12/32 (37.5%) | 21/32 (65.6%) |
AST normal/total [n (%)] | 5/32 (15.6%) | 10/32 (31.3%) | 25/32 (78.1%) |
HBV-DNA negative [n (%)] | 0/32 (0%) | 6/32 (18.8%) | 10/32 (31.3%) |
HBeAg seroconversion [n (%)] | 0/32 (0%) | 10/32 (31.3%)* | 15/32 (46.9%) |
Fibrosis improvement [n (%)] | 0/32 (0%) | 14/32 (43.8%) | NA |
Inflammation improvement [n (%)] | 0/32 (0%) | 22/32 (68.8%) | NA |